Table 1 Predictors of time to sputum culture conversion

Gender

 Female

 Male

107 (63.7)

119 (63.6)

Referent

0.900 (0.693–1.170)

0.433

Age (years)

 ≤ 40

 > 40

173 (67.3)

53 (54.1)

Referent

0.632 (0.464–0.862)

0.004

Referent

0.597 (0.414–0.859)

0.006

Baseline body weight (kg)

 < 40

 ≥ 40

72 (58.1)

154 (66.7)

Referent

0.993 (0.751–1.315)

0.963

Marital status

 Single

 Married

 Widow

78 (68.4)

143 (61.4)

5 (2.2)

Referent

0.827(0.627–1.090)

0.478 (0.193–1.183)

0.178

0.110

Referent

0.964 (0.707–1.314)

0.752 (0.281–2.013)

0.815

0.571

History of TB treatment

 No

 Yes

20 (83.3)

206 (62.2)

Referent

0.677 (0.428–1.073)

0.097

Referent

0.886 (0.541–1.450)

0.629

History of MDR-TB treatment

 No

 Yes

153 (66.5)

73 (58.4)

Referent

0.684 (0.517–0.905)

0.008

Referent

0.805 (0.599–1.081)

0.150

Baseline sputum smear grading

 Negative

 Scanty* + 1†

 + 2‡& + 3§

 Not available

38 (67.9)

68 (61.8)

117 (63.6)

3 (60)

Referent

0.652 (0.438–0.971)

0.630 (0.437–0.910)

0.393 (0.121–1.276)

0.035

0.014

0.120

Referent

0.511 (0.336–0.777)

0.523 (0.353–0.777)

0.443 (0.132–1.479)

0.002

0.001

0.186

Co-morbidity

 No

 Yes

191 (63.9)

35 (62.5)

Referent

0.850 (0.592–1.222)

0.380

Number of resistant drugs

 4–6

 7–8

 > 8

71 (71)

95 (57.2)

60 (67.4)

Referent

0.612 (0.449–0.836)

0.749 (0.530–1.060)

0.002

0.103

Referent

0.689 (0.457–1.039)

1.012 (0.572–1.790)

0.075

0.967

Resistance to all five FLD

 No

 Yes

132 (62.3)

94 (65.7)

Referent

0.828 (0.634–1.082)

0.168

Referent

0.862 (0.546–1.361)

0.525

Resistance to ethambutol

 No

 Yes

60 (65.2)

166 (63.1)

Referent

0.757 (0.562–1.019)

0.066

Referent

0.920 (0.622–1.359)

0.675

Resistance to pyrazinamide

 No

 Yes

72 (68.6)

154 (61.6)

Referent

0.810 (0.611–1.073)

0.142

Referent

1.106 (0.752–1.628)

0.608

Resistance to streptomycin

 No

 Yes

88 (62.9)

138 (64.2)

Referent

0.888 (0.667–1.136)

0.387

Resistance to ethionamide

 No

 Yes

200 (64.5)

26 (57.8)

Referent

0.670 (0.444–1.012)

0.057

Referent

0.632 (0.399–1.003)

0.051

Use of moxifloxacin

 No

 Yes

68 (57.6)

158 (66.7)

Referent

1.453 (1.092–1.934)

0.010

Referent

1.449 (0.991–2.118)

0.056

Use of para-amino salicylic acid

 No

 Yes

19 (47.5)

207 (65.7)

Referent

1.430 (0.892–2.292)

0.137

Referent

1.028 (0.619–1.707)

0.914

Use of clarithromycin

 No

 Yes

90 (61.6)

136 (65.1)

Referent

0.919 (0.703–1.200)

0.535

Use of co-amoxiclav

 No

 Yes

71 (59.7)

155 (65.7)

Referent

1.086 (0.819–1.438)

0.567

Use of bedaquiline

 No

 Yes

208 (64.6)

18 (54.5)

Referent

1.208 (0.746–1.958)

0.442

Use of delamanid

 No

 Yes

222 (64.0)

4 (50.0)

Referent

0.734 (0.273–1.975)

0.540

Use of clofazimine

 No

 Yes

109 (66.5)

117 (61.3)

Referent

1.227 (0.943–1.596)

0.128

Referent

0.884 (0.607–1.288)

0.522

Use of linezolid

 No

 Yes

67 (60.4)

159 (65.2)

Referent

1.288 (0.992–1.635)

0.159

Referent

0.991 (0.703–1.396)

0.958

Use of amikacin

 No

 Yes

181(63.7)

45 (63.4)

Referent

1.045 (0.754–1.449)

0.791

Use of capreomycin

 No

 Yes

58 (61.7)

168 (64.4)

Referent

0.995 (0.738–1.342)

0.796

Use of high dose isoniazid

 No

 Yes

210 (65.6)

16 (45.7)

Referent

0.648 (0.389–1.077)

0.094

Referent

0.463 (0.267–0.802)

0.004

Use of ethambutol

 No

 Yes

186 (64.1)

40 (61.5)

Referent

1.243 (0.883–1.751)

0.213